Gene Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene Symbol APC
Synonyms BTPS2 | DESMD | DP2 | DP2.5 | DP3 | GS | PPP1R46
Gene Description APC, adenomatous polyposis coli, is a tumor suppressor (PMID: 30562755) and multi-domain protein regulating numerous cellular functions through interaction with beta-catenin and subsequent inhibition of Wnt signalling (PMID: 10959075). APC germline mutations are associated with familial adenomatous polyposis (PMID: 30562755) and somatic mutations with colon, endometrial, NSCLC, and breast cancers (PMID: 27283171).
ACMG Incidental List v3.0:
Yes, Familial adenomatous polyposis (PMID: 34012068)
NCBI Gene ID Chromosome Map Location Canonical Transcript Gene Role
324 5 5q22.2 NM_000038 Tumor suppressor (PMID: 30606230)

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT05585320 Phase Ib/II IMM-1-104 A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT02961374 Phase II Erlotinib Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer Completed USA 1
NCT06005974 Phase II TAK-733 A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation Recruiting USA 0
NCT04851119 Phase Ib/II BC2059 Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Recruiting USA 0
NCT05919264 Phase Ib/II FOG-001 FOG-001 in Locally Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT02675946 Phase I CGX1321 CGX1321 + Pembrolizumab Cetuximab + CGX1321 + Encorafenib CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) Unknown status USA 1
NCT05761951 Phase II DKN-01 + Pembrolizumab Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer Recruiting USA 0